These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 20716141)

  • 1. Is renoprotection with RAAS blockade a failed paradigm? Have we learnt any lessons so far?
    Onuigbo MA
    Int J Clin Pract; 2010 Sep; 64(10):1341-6. PubMed ID: 20716141
    [No Abstract]   [Full Text] [Related]  

  • 2. Renoprotection by blockade of the renin-angiotensin-aldosterone system in diabetic and non-diabetic chronic kidney disease. Specific involvement of intra-renal angiotensin-converting enzyme activity in therapy resistance?
    Vogt L; Kocks MJ; Laverman GD; Navis G
    Minerva Med; 2004 Oct; 95(5):395-409. PubMed ID: 15467515
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The impact of stopping inhibitors of the renin-angiotensin system in patients with advanced chronic kidney disease.
    Ahmed AK; Kamath NS; El Kossi M; El Nahas AM
    Nephrol Dial Transplant; 2010 Dec; 25(12):3977-82. PubMed ID: 19820248
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of suspending ACE inhibitors and ARBs in advanced chronic kidney disease.
    Díaz-Domínguez ME; Fernández-Lucas M; Gomis-Couto A; Ruiz-Roso G; Teruel JL; Quereda C
    Nefrologia; 2012 May; 32(3):400-1. PubMed ID: 22592428
    [No Abstract]   [Full Text] [Related]  

  • 5. Not yet time for a paradigm shift away from angiotensin inhibitors in chronic kidney disease, but due diligence required.
    Swift PA; Andrews PA
    Int J Clin Pract; 2010 Sep; 64(10):1331-3. PubMed ID: 20716138
    [No Abstract]   [Full Text] [Related]  

  • 6. [Debate concerning the optimal blockage of the renin-angiotensin system].
    Choukroun G
    Nephrol Ther; 2010 Jan; 6 Spec No 1():H1-9. PubMed ID: 20129454
    [No Abstract]   [Full Text] [Related]  

  • 7. Renin angiotensin system blockade and nephropathy: why is it being called into question, and should it be?
    Hollenberg NK; Epstein M
    Clin J Am Soc Nephrol; 2006 Sep; 1(5):1046-8. PubMed ID: 17699325
    [No Abstract]   [Full Text] [Related]  

  • 8. Combined blockade of the renin-angiotensin system with angiotensin-converting enzyme inhibitors and angiotensin II type 1 receptor antagonists.
    Azizi M; Ménard J
    Circulation; 2004 Jun; 109(21):2492-9. PubMed ID: 15173039
    [No Abstract]   [Full Text] [Related]  

  • 9. [Renoprotection and blockade of the renin-angiotensin system: What shall we believe?].
    Kamper AL; Feldt-Rasmussen B; Strandgaard S
    Ugeskr Laeger; 2006 Apr; 168(15):1563. PubMed ID: 16640988
    [No Abstract]   [Full Text] [Related]  

  • 10. Renoprotection by blocking the RAAS in diabetic nephropathy--fact or fiction?
    Rossing P; Parving HH; de Zeeuw D
    Nephrol Dial Transplant; 2006 Sep; 21(9):2354-7; discussion 2357-8. PubMed ID: 16928724
    [No Abstract]   [Full Text] [Related]  

  • 11. Of fads, fashion, surrogate endpoints and dual RAS blockade.
    Messerli FH; Staessen JA; Zannad F
    Eur Heart J; 2010 Sep; 31(18):2205-8. PubMed ID: 20685681
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of renin-angiotensin-aldosterone system triple blockade on non-diabetic renal disease: addition of an aldosterone blocker, spironolactone, to combination treatment with an angiotensin-converting enzyme inhibitor and angiotensin II receptor blocker.
    Furumatsu Y; Nagasawa Y; Tomida K; Mikami S; Kaneko T; Okada N; Tsubakihara Y; Imai E; Shoji T
    Hypertens Res; 2008 Jan; 31(1):59-67. PubMed ID: 18360019
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Progression of chronic kidney disease: can it be prevented or arrested?
    Jaber BL; Madias NE
    Am J Med; 2005 Dec; 118(12):1323-30. PubMed ID: 16378772
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Renin inhibition and the kidney].
    Ecder T
    Turk Kardiyol Dern Ars; 2009 Oct; 37 Suppl 7():28-31. PubMed ID: 20019474
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nephroprotective action of renin-angiotensin-aldosterone system blockade in chronic kidney disease patients: the landscape after ALTITUDE and VA NEPHRON-D trails.
    Rutkowski B; Tylicki L
    J Ren Nutr; 2015 Mar; 25(2):194-200. PubMed ID: 25576239
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical trials in progression of chronic renal failure.
    Striker GE; Klahr S
    Adv Intern Med; 1997; 42():555-95. PubMed ID: 9048130
    [No Abstract]   [Full Text] [Related]  

  • 17. Effect of renin-angiotensin system blockade on calcium channel blocker-associated peripheral edema.
    Makani H; Bangalore S; Romero J; Wever-Pinzon O; Messerli FH
    Am J Med; 2011 Feb; 124(2):128-35. PubMed ID: 21295192
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Progression of renal disease: renoprotective specificity of renin-angiotensin system blockade.
    Griffin KA; Bidani AK
    Clin J Am Soc Nephrol; 2006 Sep; 1(5):1054-65. PubMed ID: 17699327
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Significance of RAAS inhibition in diabetic nephropathy].
    Tsuruya K; Toyonaga J
    Nihon Rinsho; 2012 Jul; 70 Suppl 5():411-8. PubMed ID: 23156430
    [No Abstract]   [Full Text] [Related]  

  • 20. Angiotensin receptor blockers: RAAS blockade and renoprotection.
    Ruilope LM
    Curr Med Res Opin; 2008 May; 24(5):1285-93. PubMed ID: 18366863
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.